Executive Medical Director, Global Med Affrs Lead - Tezepelumab & Pulmonary Pipeline

Thousand Oaks, CA, US
Mar 22, 2019
Required Education
Position Type
Full time
Executive Medical Director, Medical Affairs, Global Medical Affairs Lead - Tezepelumab and pulmonary pipeline

Job Summary

The Executive Medical Director, Global Medical Affairs Lead will be accountable for development and execution of the global medical affairs strategy for Tezepelumab and early pulmonary pipeline with the objective of maximizing Amgen's value proposition.

The Global Medical Affairs Lead (GMAL) for Tezepelumab is responsible for:
  • Developing the global medical strategy in partnership with AstraZeneca for Tezepelumab through deep understanding of medical practice to maximize access and reimbursement
  • Contributing to the product strategy for Tezepelumab and early pulmonary pipeline
  • Developing and leading execution of global medical affairs strategy, including external stakeholder management, communication, evidence generation, and medical education
  • Developing and leading execution of a global medical communication strategy, including clinical narrative framework, scientific platform, core content, congresses, and publications
  • Developing global external stakeholder engagement strategy to strengthen understanding of the unmet need and medical value of Tezepelumab and early pulmonary pipeline to appropriate patients
  • Facilitating the build-up of Amgen's reputation as a science-based and patient focused reliable partner
  • Partnering on evidence generation and ensuring key regional/local needs are addressed
  • Developing and leading execution of medical educational strategy
  • Providing medical insights and advice

Basic Qualifications

  • MD/DO degree from an accredited medical school OR PhD OR PharmD AND
  • 6 years of Medical Affairs experience in Pulmonology AND
  • Clinical and disease knowledge base in asthma

Preferred Qualifications
  • MD plus accredited fellowship in Pulmonology, board certified or board eligible
  • 10 or more years of Medical Affairs experience in the biopharmaceutical industry (biotech, pharmaceutical or CRO) that includes collaborations with integrated delivery networks, accountable care organizations, and/or payers
  • 3 or more years of clinical research experience and/or basic science combined with clinical teaching and patient care activities
  • Familiarity with global regulatory organizations, guidelines, and practices
  • Knowledge of Good Clinical Practices (GCP) and global regulations and guidelines
  • History of solving problems while exhibiting superior judgment and a balanced, realistic understanding of issues
  • Knowledge of pharmaceutical product development, product lifecycle, and commercialization processes, including but not limited to, clinical operations, commercial, regulatory, and medical affairs

Tezepelumab is a potential first-in-class new medicine blocking TSLP, an epithelial cytokine, critical in the initiation and persistence of airway inflammation. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells resulting in the prevention of asthma exacerbations and improved asthma control. Tezepelumab's upstream mode of action at the start of the inflammatory cascade may explain why it affects multiple pathways and benefits a broad population of patients with and without signs of T2 inflammation.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is an Equal Opportunity employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.